Third Rock Ventures
SelectiveFiled to raiseBoston, MALast fund filed January 2026Biotechnology, Pharmaceuticals, Business Services
Boston, MALast fund filed January 2026Biotechnology, Pharmaceuticals, Business Services
0 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Third Rock Ventures VII, L.P.Filed to raise, with no closing reported yet. | January 2026 | $750.0M | $0 | 0 |
| Third Rock Ventures VI, L.P. | May 2022 | $1.11B | $1.11B | 65 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. Form D carries no per-investor amount, so a firm’s own cheque is not recoverable here.
10 partners are named across this firm’s filings, 0 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats, 24mo |
|---|---|---|---|
| David KaufmanOn the current fund | Slowing | None listed | 1 |
| Kevin GillisOn the current fund | Slowing | None listed | 1 |
| Reid HuberOn the current fund | Slowing | None listed | 1 |
| Abbie CelnikerOn the current fund | Quiet | None listed | 0 |
| Andrea Van Elsas | Quiet | None listed | 0 |
| Cary PfefferOn the current fund | Quiet | None listed | 0 |
| Jeffrey TongOn the current fund | Quiet | None listed | 0 |
| Jigar Raythatha | Quiet | None listed | 0 |
| Neil ExterOn the current fund | Quiet | None listed | 0 |
| Robert TepperOn the current fund | Quiet | None listed | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. On a firm it is the total across its partners, so an active firm may be four partners taking one seat each rather than one person moving fast. It undercounts partners who invest without taking a board seat, and Form D lags a closing by weeks — so Quiet means the paperwork is quiet, not the person.